Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pariksith Singh

Internal Medicine Spring Hill, FL Medical Doctor

NPI 1417989625 CMS profile 63822

3021 Commercial Way, Spring Hill, FL 34606

Open in the dashboard

General payments

$3,765

16 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pariksith Singh of Spring Hill, FL is reported in the CMS Open Payments database as having received $3,765 across 16 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $73 3
2024 General $3,408 1
2023 General $19 1
2022 General $14 1
2021 General $113 3
2019 General $138 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pariksith Singh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Pariksith Singh were reported at $73. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Pariksith Singh Internal Medicine median Middle half National median
2019 $138 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $113 $135 $37–$521 $132
2022 $14 $141 $42–$496 $149
2023 $19 $149 $45–$519 $160
2024 $3,408 $154 $47–$537 $164
2025 $73 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Olympus America Inc. $3,408 1 payment
  2. Pfizer Inc. $147 7 payments
  3. Astellas Pharma US Inc $85 1 payment
  4. Insmed, Inc. $30 1 payment
  5. Amgen Inc. $28 2 payments
  6. SI-BONE, Inc. $25 1 payment
  7. GlaxoSmithKline, LLC. $16 1 payment
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $14 1 payment
  9. AbbVie, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Debt forgiveness $3,408 1 payment
  2. Education $188 4 payments
  3. Food and Beverage $169 11 payments
Products named General payments · program years 2019–2025
  1. EVIS EXERA III COLONOVIDEOSCOPE $3,408 1 payment
  2. CHANTIX $75 1 payment
  3. ELIQUIS $53 5 payments
  4. Arikayce $30 1 payment
  5. NURTEC ODT $19 1 payment
  6. PAXLOVID $19 1 payment
  7. PREVNAR 20 $19 1 payment
  8. COMIRNATY $19 1 payment
  9. ABRYSVO $19 1 payment
  10. TRELEGY ELLIPTA $16 1 payment
  11. Other $41 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 91 drugs

Part D claims

5,110

Median for Internal Medicine: 777

Drug cost

$188,595

Median for Internal Medicine: $73,373

Branded share of claims

22.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 29 $27,989
Ozempic Semaglutide Brand 18 $22,224
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $16,576
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 406 $10,966
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 44 $9,127
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 26 $8,715
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 13 $7,909
Wixela Inhub Fluticasone Propion/Salmeterol Brand 20 $6,218
Oxycodone Hcl Generic 195 $5,691
Pregabalin Generic 103 $5,231

The 10 drugs with the highest cost, of 91 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$40,341

Of which drugs: $2,233

Medicare patients

341

Average age 78

Services billed

9,283

218 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 43%
Ischemic heart disease 43%
Chronic kidney disease 40%
COPD 35%
Depression 29%
Heart failure 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 15 302 $70
Injection, ceftriaxone sodium, per 250 mg J0696 Office 24 179 $63
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 17 34 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record